eprintid: 35529
rev_number: 19
eprint_status: archive
userid: 3730
dir: disk0/00/03/55/29
datestamp: 2024-10-23 14:54:24
lastmod: 2024-11-04 12:17:30
status_changed: 2024-10-23 14:54:24
type: article
metadata_visibility: show
creators_name: Itzel, Timo
creators_name: Falconer, Thomas
creators_name: Roig, Ana
creators_name: Daza, Jimmy
creators_name: Park, Jimyung
creators_name: Cheong, Jae Youn
creators_name: Park, Rae Woong
creators_name: Wiest, Isabella
creators_name: Ebert, Matthias P
creators_name: Hripcsak, George
creators_name: Teufel, Andreas
title: Efficacy of Co-Medications in Patients with Alcoholic Liver Disease
ispublished: pub
subjects: ddc-610
divisions: i-61100
divisions: i-65300
note: Dieser Beitrag ist aufgrund einer (DFG-geförderten) Allianz bzw. Nationallizenz frei zugänglich. *** This publication is freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.
abstract: Background: Alcoholic liver disease (ALD) is still increasing and leads to acute liver injury but also liver cirrhosis and subsequent complications such as liver failure or hepatocellular carcinoma (HCC). As most patients fail to achieve alcohol abstinence, it is essential to identify alternative treatment options in order to improve the outcome of ALD patients. Methods: Evaluating two large cohorts of patients with ALD from the USA and Korea with a total of 12,006 patients, we investigated the effect on survival of aspirin, metformin, metoprolol, dopamine, and dobutamine drugs in patients with ALD between 2000 and 2020. Patient data were obtained through the “The Observational Health Data Sciences and Informatics consortium,” an open-source, multi-stakeholder, and interdisciplinary collaborative effort. Results: The use of aspirin (p = 0.000, p = 0.000), metoprolol (p = 0.002, p = 0.000), and metformin (p = 0.000, p = 0.000) confers a survival benefit for both AUSOM- and NY-treated cohorts. Need of catecholamines dobutamine (p = 0.000, p = 0.000) and dopamine (p = 0.000, p = 0.000) was strongly indicative of poor survival. β-Blocker treatment with metoprolol (p = 0.128, p = 0.196) or carvedilol (p = 0.520, p = 0.679) was not shown to be protective in any of the female subgroups. Conclusion: Overall, our data fill a large gap in long-term, real-world data on patients with ALD, confirming an impact of metformin, acetylsalicylic acid, and β-blockers on ALD patient’s survival. However, gender and ethnic background lead to diverse efficacy in those patients.
date: 2023-09
date_type: published
publisher: Karger
id_scheme: DOI
id_number: 10.11588/heidok.00035529
official_url: https://doi.org/10.1159/000529914
ppn_swb: 1907415459
own_urn: urn:nbn:de:bsz:16-heidok-355291
language: eng
bibsort: ITZELTIMOEFFICACYOF2023
full_text_status: public
publication: Digestive Diseases
volume: 41
number: 5
pagerange: 780-788
pages: 9
issn: 0257-2753 (Druck-Ausg.), 1421-9875 (Online-Ausg.)
edition: Zweitveröffentlichung
citation:   Itzel, Timo ; Falconer, Thomas ; Roig, Ana ; Daza, Jimmy ; Park, Jimyung ; Cheong, Jae Youn ; Park, Rae Woong ; Wiest, Isabella ; Ebert, Matthias P ; Hripcsak, George ; Teufel, Andreas  (2023) Efficacy of Co-Medications in Patients with Alcoholic Liver Disease.  Digestive Diseases, 41 (5).  pp. 780-788.  ISSN 0257-2753 (Druck-Ausg.), 1421-9875 (Online-Ausg.)     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/35529/1/000529914.pdf